Clinical Trial: Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093554) titled 'Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma' on July 23.

Brief Summary: This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Study Start Date: Dec. 01, 2025

Study Type: INTERVENTIONAL

Condition: Relapse Multiple Myeloma Refractory Multiple Myeloma

Intervention: DRUG: Talquetamab

Talquetamab will be administered subcutaneously.

DRUG: Ciltacabtagene ...